Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

Yuka Tanaka, MD, Takayuki Tabayashi, MD PhD, Yasuyuki Takahashi, MD PhD, Yuta Kimura, MD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, Masahiro Kizaki, MD PhD

Blood (2018) 132 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2018-99-116247

Published: 2018

Journal Articles

The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders

Michihide Tokuhira, Yuta Kimura, MD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD PhD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Shuji Momose, MD PhD, Morihiro Higashi, MD PhD, Tabayashi Takayuki, MD PhD, Reiko Nakaseko, MD PhD, Jun-ichi Tamaru, MDPhD, Masahiro Kizaki, MDPhD

Blood (2018) 132 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2018-99-114382

Published: 2018

Journal Articles

HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma

Takeshi Harada, MD PhD, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Shohei Kikuchi, MD PhD, Morihiko Sagawa, MD PhD, Yu-Tzu Tai, PhD, Ralph Mazitschek, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4472.

https://doi.org/10.1182/blood.V128.22.4472.4472

Published: 2016

Journal Articles

Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma

Morihiko Sagawa, MD PhD, Hiroto Ohguchi, MD PhD, Takeshi Harada, MD PhD, Mehmet K. Samur, PhD, Yu-Tzu Tai, PhD, Nikhil C Munshi, MD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 360.

https://doi.org/10.1182/blood.V128.22.360.360

Published: 2016

Journal Articles

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Takayuki Tabayashi, MD PhD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Anan-Nemoto, MDPhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 3256.

https://doi.org/10.1182/blood.V128.22.3256.3256

Published: 2016

Journal Articles

Successful Management of Transplant-Ineligible Patients with Refractory/Relapsed Multiple Myeloma By Using a Biweekly or Longer Modified Bortezomib Schedule As Interval Maintenance therapy

Michihide Tokuhira, MD PhD, Yuta Kimura, MD, Tatsuki Tomikawa, Yasuyuki Takahashi, Morihiko Sagawa, MD PhD, Tomoe Nemoto, MD, Takayuki Tabayashi, MD PhD, Reiko Watanabe, MD PhD, Masahiro Kizaki, MD PhD

Blood (2014) 124 (21): 5758.

https://doi.org/10.1182/blood.V124.21.5758.5758

Published: 2014

Journal Articles

Targeting the Wnt/β-Catenin Signaling Pathway in Multiple Myeloma: A Possible New Therapeutic Approach to Overcome Bortezomib-Resistance

Takayuki Tabayashi, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Nemoto, MD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD, Shigehisa Mori, MD, Masahiro Kizaki, MD

Blood (2014) 124 (21): 3372.

https://doi.org/10.1182/blood.V124.21.3372.3372

Published: 2014

Journal Articles

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2013) 122 (21): 4427.

https://doi.org/10.1182/blood.V122.21.4427.4427

Published: 2013

Journal Articles

A Biomarker Obtained From Whole Peripheral Blood Predicts Response to Bortezomib: Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan.

Takashi Watanabe, MD, PhD, Masato Mitsuhashi, MD, PhD, Morihiko Sagawa, MD, PhD, Kenshi Suzuki, MD, PhD, Masaki Ri, MD, PhD, Masahiro Abe, MD, PhD, Ken Ohmachi, MD, Yasunori Nakagawa, MD, PhD, Shingen Nakamura, MD, Mizuki Chosa, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2012) 120 (21): 2954.

https://doi.org/10.1182/blood.V120.21.2954.2954

Published: 2012

Journal Articles

Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan

Blood (2012) 120 (21): 1816.

https://doi.org/10.1182/blood.V120.21.1816.1816

Published: 2012

Journal Articles

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Nemoto, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2012) 120 (21): 2939.

https://doi.org/10.1182/blood.V120.21.2939.2939

Published: 2012

Journal Articles

Gold Compound Auranofin (RIDAURA®) Induces Apoptosis of Human Myeloma Cells by Targeting STAT3 and NF-κB Pathways, with Clinical Potential.

Morihiko Sagawa, MD, Aya Nakaya, MD, Tatsuki Tomikawa, MD, Yuichiro Haba, MD, Tomoe Nemoto, MD, Kyoko Hanzawa, MD, Reiko Watanabe, MD, Michihide Tokuhira, MD, Shigehisa Mori, MD, Hideo Uchida, MD, Akihiro Muto, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2009) 114 (22): 3837.

https://doi.org/10.1182/blood.V114.22.3837.3837

Published: 2009

Journal Articles

Myeloperoxidase (MPO) Is a Key Regulator of Oxidative Stress-Mediated Apoptosis in Myeloid Leukemic Cells.

Masahiro Kizaki, MD, Tomonori Nakazato, MD, Morihiko Sagawa, MD, Kenji Yamato, MD, Mingji Xian, MD, Yasuo Ikeda, MD

Blood (2006) 108 (11): 1923.

https://doi.org/10.1182/blood.V108.11.1923.1923

Published: 2006

Journal Articles

A New Disulfide-Linked Dimer of a Single-Chain Antibody Fragment Against Human CD47 Induces Apoptosis in Lymphoid Malignant Cells In Vitro and In Vivo Via the HIF-1α Pathway: A Possible Novel Therapeutic Agent for B-CLL.

Morihiko Sagawa, MD, Takatsune Shimizu, MD, Mingji Xian, MD, Aki Chizuka, MD, Naoshi Fukushima, PhD, Yasuko Kinoshita, PhD, Iwao Ohizumi, PhD, Yasuo Ikeda, MD, Hisafumi Okabe, PhD, Masahiro Kizaki, MD

Blood (2006) 108 (11): 2097.

https://doi.org/10.1182/blood.V108.11.2097.2097

Published: 2006

Journal Articles

Green Tea Component, Catechin, Induces Apoptosis of Myeloid Leukemic Cells Via Myeloperoxidase (MPO)-Dependent Highly Reactive Oxygen Species (ROS) Production.

Tomonori Nakazato, MD, Kenji Yamato, MD, Morihiko Sagawa, MD, Yuriko Nishiyama, MD, Yasuo Ikeda, MD, Masahiro Kizaki, MD

Blood (2005) 106 (11): 4429.

https://doi.org/10.1182/blood.V106.11.4429.4429

Published: 2005

NARROW

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders

HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma

Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Successful Management of Transplant-Ineligible Patients with Refractory/Relapsed Multiple Myeloma By Using a Biweekly or Longer Modified Bortezomib Schedule As Interval Maintenance therapy

Targeting the Wnt/β-Catenin Signaling Pathway in Multiple Myeloma: A Possible New Therapeutic Approach to Overcome Bortezomib-Resistance

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

A Biomarker Obtained From Whole Peripheral Blood Predicts Response to Bortezomib: Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan.

Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Gold Compound Auranofin (RIDAURA®) Induces Apoptosis of Human Myeloma Cells by Targeting STAT3 and NF-κB Pathways, with Clinical Potential.

Myeloperoxidase (MPO) Is a Key Regulator of Oxidative Stress-Mediated Apoptosis in Myeloid Leukemic Cells.

A New Disulfide-Linked Dimer of a Single-Chain Antibody Fragment Against Human CD47 Induces Apoptosis in Lymphoid Malignant Cells In Vitro and In Vivo Via the HIF-1α Pathway: A Possible Novel Therapeutic Agent for B-CLL.

Green Tea Component, Catechin, Induces Apoptosis of Myeloid Leukemic Cells Via Myeloperoxidase (MPO)-Dependent Highly Reactive Oxygen Species (ROS) Production.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only